HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
October 25, 2024 | 10:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Rigel Pharmaceuticals, maintaining a price target of $57. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and a high price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term. The $57 price target suggests significant upside potential from current levels.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100